{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T20:51:10Z","timestamp":1780692670071,"version":"3.54.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012232","name":"National Key Clinical Specialty Discipline Construction Program of China","doi-asserted-by":"publisher","award":["BYSYDL2021006"],"award-info":[{"award-number":["BYSYDL2021006"]}],"id":[{"id":"10.13039\/501100012232","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012232","name":"National Key Clinical Specialty Discipline Construction Program of China","doi-asserted-by":"publisher","award":["BYSYDL2021006"],"award-info":[{"award-number":["BYSYDL2021006"]}],"id":[{"id":"10.13039\/501100012232","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s00277-025-06379-x","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T04:35:09Z","timestamp":1745555709000},"page":"2361-2371","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment outcomes of BTK inhibitors and venetoclax with or without anti-CD20 monoclonal antibody in relapsed or refractory mantle cell lymphoma"],"prefix":"10.1007","volume":"104","author":[{"given":"Ping","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo-Zi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Tong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Long","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4958-2489","authenticated-orcid":false,"given":"Hong-Mei","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"issue":"1","key":"6379_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","volume":"117","author":"P Perez-Galan","year":"2011","unstructured":"Perez-Galan P, Dreyling M, Wiestner A (2011) Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 117(1):26\u201338. https:\/\/doi.org\/10.1182\/blood-2010-04-189977","journal-title":"Blood"},{"issue":"2","key":"6379_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/bjh.17419","volume":"195","author":"E Silkenstedt","year":"2021","unstructured":"Silkenstedt E, Linton K, Dreyling M (2021) Mantle cell lymphoma-advances in molecular biology, prognostication and treatment approaches. Br J Haematol 195(2):162\u2013173. 10.1111 \/bjh.17419","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"6379_CR3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/hon.3149","volume":"41","author":"E Silkenstedt","year":"2023","unstructured":"Silkenstedt E, Dreyling M (2023) Mantle cell lymphoma-Update on molecular biology, prognostication and treatment approaches. Hematol Oncol 41(Suppl 1):36\u201342. https:\/\/doi.org\/10.1002\/hon.3149","journal-title":"Hematol Oncol"},{"issue":"5","key":"6379_CR4","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/ajh.26523","volume":"97","author":"P Jain","year":"2022","unstructured":"Jain P, Wang ML (2022) Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. Am J Hematol 97(5):638\u2013656. https:\/\/doi.org\/10.1002\/ajh.26523","journal-title":"Am J Hematol"},{"issue":"26","key":"6379_CR5","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMra2202672","volume":"386","author":"JO Armitage","year":"2022","unstructured":"Armitage JO, Longo DL, Mantle-Cell Lymphoma (2022) N Engl J Med 386(26):2495\u20132506. https:\/\/doi.org\/10.1056\/NEJMra2202672","journal-title":"N Engl J Med"},{"issue":"36","key":"6379_CR6","doi-asserted-by":"publisher","first-page":"4302","DOI":"10.1200\/JCO.20.02287","volume":"38","author":"P Jain","year":"2020","unstructured":"Jain P, Dreyling M, Seymour JF et al (2020) High-Risk mantle cell lymphoma: definition, current challenges, and management. J Clin Oncol 38(36):4302\u20134316. https:\/\/doi.org\/10.1200\/JCO.20.02287","journal-title":"J Clin Oncol"},{"issue":"1","key":"6379_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11899-021-00605-9","volume":"16","author":"E Nabrinsky","year":"2021","unstructured":"Nabrinsky E, Danilov AV, Koller PB (2021) High-Risk mantle cell lymphoma in the era of novel agents. Curr Hematol Malig Rep 16(1):8\u201318. https:\/\/doi.org\/10.1007\/s11899-021-00605-9","journal-title":"Curr Hematol Malig Rep"},{"issue":"9","key":"6379_CR8","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1038\/s41375-023-01977-y","volume":"37","author":"G Scheubeck","year":"2023","unstructured":"Scheubeck G, Jiang L, Hermine O et al (2023) Clinical outcome of mantle cell lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression). Leukemia 37(9):1887\u20131894. https:\/\/doi.org\/10.1038\/s41375-023-01977-y","journal-title":"Leukemia"},{"issue":"16","key":"6379_CR9","doi-asserted-by":"publisher","first-page":"6860","DOI":"10.1002\/cam4.2565","volume":"8","author":"Y-W Jeon","year":"2019","unstructured":"Jeon Y-W, Yoon S, Min GJ et al (2019) Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience. Cancer Med 8(16):6860\u20136870. https:\/\/doi.org\/10.1002\/cam4.2565","journal-title":"Cancer Med"},{"key":"6379_CR10","doi-asserted-by":"publisher","unstructured":"Tivey A, Shotton R, Eyre TA et al (2023) Ibrutinib as first line therapy for mantle cell lymphoma: A multicentre, real-world UK study.Blood Adv.;21: bloodadvances. 2023011152. https:\/\/doi.org\/10.1182\/bloodadvances.2023011152","DOI":"10.1182\/bloodadvances.2023011152"},{"issue":"3","key":"6379_CR11","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41375-020-01013-3","volume":"35","author":"C Visco","year":"2021","unstructured":"Visco C, Di Rocco A, Evangelista A et al (2021) Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. Leukemia 35(3):787\u2013795. https:\/\/doi.org\/10.1038\/s41375-020-01013-3","journal-title":"Leukemia"},{"issue":"2","key":"6379_CR12","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1016\/S2352-3026(22)00355-6","volume":"10","author":"TE Lew","year":"2023","unstructured":"Lew TE, Minson A, Dickinson M et al (2023) Treatment approaches for patients with TP53-mutated mantle cell lymphoma. Lancet Haematol 10(2):e142\u2013e154. https:\/\/doi.org\/10.1016\/S2352-3026(22)00355-6","journal-title":"Lancet Haematol"},{"key":"6379_CR13","doi-asserted-by":"publisher","unstructured":"Wallace D, Reagan PM (2021) Novel treatments for mantle cell lymphoma: from targeted therapies to CAR T cells.Drugs. 81(6):669\u2013684. https:\/\/doi.org\/10.1007\/s40265-021-01497-y","DOI":"10.1007\/s40265-021-01497-y"},{"issue":"1","key":"6379_CR14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12943-023-01755-5","volume":"22","author":"Z Huang","year":"2023","unstructured":"Huang Z, Chavda VP (2023) Bezbaruah R,etal.CAR T-Cell therapy for the management of mantle cell lymphoma. Mol Cancer 22(1):67. https:\/\/doi.org\/10.1186\/s12943-023-01755-5","journal-title":"Mol Cancer"},{"issue":"1","key":"6379_CR15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/bjh.19131","volume":"204","author":"TA Eyre","year":"2024","unstructured":"Eyre TA, Bishton MJ, McCulloch R et al (2024) Diagnosis and management of mantle cell lymphoma: A British society for haematology guideline. Br J Haematol 204(1):108\u2013126. https:\/\/doi.org\/10.1111\/bjh.19131","journal-title":"Br J Haematol"},{"issue":"14","key":"6379_CR16","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A et al (2020) KTE-X19 CAR T-Cell therapy in relapsed or refractory Mantle-Cell lymphoma. N Engl J Med 382(14):1331\u20131342. https:\/\/doi.org\/10.1056\/NEJMoa1914347","journal-title":"N Engl J Med"},{"issue":"3","key":"6379_CR17","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1200\/JCO.21.02370","volume":"41","author":"M Wang","year":"2023","unstructured":"Wang M, Munoz J, Goy A et al (2023) Three-Year Follow-Up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including High-Risk subgroups, in the ZUMA-2 study. J Clin Oncol 41(3):555\u2013567. https:\/\/doi.org\/10.1200\/JCO.21.02370","journal-title":"J Clin Oncol"},{"issue":"14","key":"6379_CR18","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1200\/JCO.22.01797","volume":"41","author":"Y Wang","year":"2023","unstructured":"Wang Y, Jain P, Locke FL et al (2023) Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in Standard-of-Care practice: results from the US lymphoma CAR T consortium. J Clin Oncol 41(14):2594\u20132606. https:\/\/doi.org\/10.1200\/JCO.22.01797","journal-title":"J Clin Oncol"},{"issue":"5","key":"6379_CR19","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1182\/blood.2021013326","volume":"139","author":"TA Eyre","year":"2022","unstructured":"Eyre TA, Cheah CY, Wang ML (2022) Therapeutic options for relapsed\/refractory mantle cell lymphoma. Blood 139(5):666\u2013677. https:\/\/doi.org\/10.1182\/blood.2021013326","journal-title":"Blood"},{"key":"6379_CR20","doi-asserted-by":"crossref","unstructured":"Davids MS, Roberts AW, Seymour JF et al (2017) Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol 35(8):826\u2013833. 10.1200\/ JCO. 2016.70.4320","DOI":"10.1200\/JCO.2016.70.4320"},{"issue":"13","key":"6379_CR21","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","volume":"378","author":"CS Tam","year":"2018","unstructured":"Tam CS, Anderson MA, Pott C et al (2018) Ibrutinib plus venetoclax for the treatment of Mantle-Cell lymphoma. N Engl J Med 378(13):1211\u20131223. https:\/\/doi.org\/10.1056\/NEJMoa1715519","journal-title":"N Engl J Med"},{"issue":"1","key":"6379_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s13045-021-01188-x","volume":"14","author":"M Wang","year":"2021","unstructured":"Wang M, Ramchandren R, Chen R et al (2021) Concurrent ibrutinib plus venetoclax in relapsed\/ refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study. J Hematol Oncol 14(1):179. https:\/\/doi.org\/10.1186\/s13045-021-01188-x","journal-title":"J Hematol Oncol"},{"issue":"7","key":"6379_CR23","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1182\/blood.2020008727","volume":"137","author":"S Le Gouill","year":"2021","unstructured":"Le Gouill S, Morschhauser F, Chiron D et al (2021) Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1\/2 trial. Blood 137(7):877\u2013887. https:\/\/doi.org\/10.1182\/blood.2020008727","journal-title":"Blood"},{"issue":"13","key":"6379_CR24","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1182\/bloodadvances.2022008916","volume":"7","author":"Y Sawalha","year":"2023","unstructured":"Sawalha Y, Goyal S, Switchenko JM et al (2023) A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma. Blood Adv 7(13):2983\u20132993. https:\/\/doi.org\/10.1182\/bloodadvances.2022008916","journal-title":"Blood Adv"},{"issue":"2","key":"6379_CR25","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s10147-023-02443-6","volume":"29","author":"H Goto","year":"2024","unstructured":"Goto H, Ito S, Kizaki M et al (2024) Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed\/refractory mantle cell lymphoma. Int J Clin Oncol 29(2):232\u2013240. https:\/\/doi.org\/10.1007\/s10147-023-02443-6","journal-title":"Int J Clin Oncol"},{"issue":"5","key":"6379_CR26","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1182\/bloodadvances.2021005357","volume":"6","author":"CA Portell","year":"2022","unstructured":"Portell CA, Wages NA, Kahl BS et al (2022) Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma. Blood Adv 6(5):1490\u20131498. https:\/\/doi.org\/10.1182\/bloodadvances.2021005357","journal-title":"Blood Adv"},{"key":"6379_CR27","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA et al (2016) The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood 127:2375\u20132390. https:\/\/doi.org\/10.1182\/blood-2016-01-643569","journal-title":"Blood"},{"issue":"26","key":"6379_CR28","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa220181741","volume":"386","author":"ML Wang","year":"2022","unstructured":"Wang ML, Jurczak W, Jerkeman M et al (2022) Ibrutinib plus Bendamustine and rituximab in untreated Mantle-Cell lymphoma. N Engl J Med 386(26):2482\u20132494. https:\/\/doi.org\/10.1056\/NEJMoa220181741","journal-title":"N Engl J Med"},{"key":"6379_CR29","doi-asserted-by":"publisher","unstructured":"Wang ML, Jain P, Zhao S et al (2022) Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (\u2264\u200965 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.lancet oncol. 23(3):406\u2013415. https:\/\/doi.org\/10.1016\/S1470-2045(21)00638-0","DOI":"10.1016\/S1470-2045(21)00638-0"},{"key":"6379_CR30","doi-asserted-by":"publisher","unstructured":"Davis JE, Handunnetti SM, Ludford-Menting M et al (2020) Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy.blood adv. 4(19):4849\u20134859. https:\/\/doi.org\/10.1182\/bloodadvances.2020002810","DOI":"10.1182\/bloodadvances.2020002810"},{"issue":"26","key":"6379_CR31","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1182\/blood.2023020240","volume":"141","author":"PA Thompson","year":"2023","unstructured":"Thompson PA, Tam CS (2023) Pirtobrutinib: a new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders. Blood 141(26):3137\u20133142. https:\/\/doi.org\/10.1182\/blood.2023020240","journal-title":"Blood"},{"issue":"1","key":"6379_CR32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13045-023-01496-4","volume":"16","author":"N Jain","year":"2023","unstructured":"Jain N, Mamgain M, Chowdhury SM et al (2023) Beyond Bruton\u2019s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody-drug conjugates, CAR T-cells, and novel agents. J Hematol Oncol 16(1):99. https:\/\/doi.org\/10.1186\/s13045-023-01496-4","journal-title":"J Hematol Oncol"},{"issue":"10","key":"6379_CR33","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.3390\/pharmaceutics14102238","volume":"14","author":"A Ghaderi","year":"2022","unstructured":"Ghaderi A, Zhong W, Okhovat MA et al (2022) A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of mantle cell lymphoma (MCL) cells. Pharmaceutics 14(10):2238. https:\/\/doi.org\/10.3390\/pharmaceutics14102238","journal-title":"Pharmaceutics"},{"issue":"1","key":"6379_CR34","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13045-021-01143-w","volume":"14","author":"V Jiang","year":"2021","unstructured":"Jiang V, Liu Y, Jordan A et al (2021) The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma. J Hematol Oncol 14(1):132. https:\/\/doi.org\/10.1186\/s13045-021-01143-w","journal-title":"J Hematol Oncol"},{"issue":"5","key":"6379_CR35","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/annonc\/mdv074","volume":"26","author":"D Chihara","year":"2015","unstructured":"Chihara D, Asano N, Ohmachi K et al (2015) Ki-67 is a strong predictor of central nervous system relapse in patients with mantle cell lymphoma (MCL). Ann Oncol 26(5):966\u2013973. 10.1093 \/annonc\/mdv074","journal-title":"Ann Oncol"},{"issue":"8","key":"6379_CR36","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1093\/annonc\/mdt139","volume":"24","author":"CY Cheah","year":"2013","unstructured":"Cheah CY, George A, Gin\u00e9 E et al (2013) Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European mantle cell lymphoma network. Ann Oncol 24(8):2119\u20132123. https:\/\/doi.org\/10.1093\/annonc\/mdt139","journal-title":"Ann Oncol"},{"issue":"14","key":"6379_CR37","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1182\/blood-2015-05-647834","volume":"126","author":"S Bernard","year":"2015","unstructured":"Bernard S, Goldwirt L, Amorim S et al (2015) Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse. Blood 126(14):1695\u20131698. https:\/\/doi.org\/10.1182\/blood-2015-05-647834","journal-title":"Blood"},{"issue":"17","key":"6379_CR38","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1182\/blood.2022015560","volume":"140","author":"C Rusconi","year":"2022","unstructured":"Rusconi C, Cheah CY, Eyre TA et al (2022) Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse. Blood 140(17):1907\u20131916. https:\/\/doi.org\/10.1182\/blood.2022015560","journal-title":"Blood"},{"issue":"1","key":"6379_CR39","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1186\/s13256-021-02939-7","volume":"15","author":"N Albiol","year":"2021","unstructured":"Albiol N, Novelli S, Mozos A et al (2021) Venetoclax in relapsed\/refractory blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement: a case report and review of the literature. J Med Case Rep 15(1):326. https:\/\/doi.org\/10.1186\/s13256-021-02939-7","journal-title":"J Med Case Rep"},{"issue":"5","key":"6379_CR40","doi-asserted-by":"publisher","first-page":"e222","DOI":"10.3324\/haematol.2018.213157","volume":"104","author":"G Reda","year":"2019","unstructured":"Reda G, Cassin R, Dovrtelova G et al (2019) Venetoclax penetrates in cerebrospinal fluid and May be effective in chronic lymphocytic leukemia with central nervous system involvement. Haematologica 104(5):e222\u2013e223. https:\/\/doi.org\/10.3324\/haematol.2018.213157","journal-title":"Haematologica"},{"key":"6379_CR41","doi-asserted-by":"publisher","unstructured":"Vu K (2023) Frank MJ.CAR T-cell therapy for mantle cell lymphoma with central nervous system relapse.blood adv. 7(3):375\u2013378. https:\/\/doi.org\/10.1182\/bloodadvances.2022008031","DOI":"10.1182\/bloodadvances.2022008031"},{"key":"6379_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2024.2304622","volume":"22","author":"AC Lionel","year":"2024","unstructured":"Lionel AC, Gurumurthi A, Fetooh A et al (2024) Efficacy and safety of Brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement.leuk lymphoma. Jan 22:1\u20135. https:\/\/doi.org\/10.1080\/10428194.2024.2304622","journal-title":"Jan"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06379-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06379-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06379-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T03:14:23Z","timestamp":1746414863000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06379-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["6379"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06379-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"27 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}